BIOMAT Database Logo BIOMAT Database Logo

Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. 2015

Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Department of Gene Expression, Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University, Umultowska 89, 61-614 Poznan, Poland.

Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystemic disorder caused by expansion of CTG triplet repeats in 3'-untranslated region of DMPK gene. The pathomechanism of DM1 is driven by accumulation of toxic transcripts containing expanded CUG repeats (CUG(exp)) in nuclear foci which sequester several factors regulating RNA metabolism, such as Muscleblind-like proteins (MBNLs). In this work, we utilized very short chemically modified antisense oligonucleotides composed exclusively of locked nucleic acids (all-LNAs) complementary to CUG repeats, as potential therapeutic agents against DM1. Our in vitro data demonstrated that very short, 8- or 10-unit all-LNAs effectively bound the CUG repeat RNA and prevented the formation of CUG(exp)/MBNL complexes. In proliferating DM1 cells as well as in skeletal muscles of DM1 mouse model the all-LNAs induced the reduction of the number and size of CUG(exp) foci and corrected MBNL-sensitive alternative splicing defects with high efficacy and specificity. The all-LNAs had low impact on the cellular level of CUG(exp)-containing transcripts and did not affect the expression of other transcripts with short CUG repeats. Our data strongly indicate that short all-LNAs complementary to CUG repeats are a promising therapeutic tool against DM1.

UI MeSH Term Description Entries
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009223 Myotonic Dystrophy Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2. Dystrophia Myotonica,Myotonic Dystrophy, Congenital,Myotonic Myopathy, Proximal,Steinert Disease,Congenital Myotonic Dystrophy,Dystrophia Myotonica 1,Dystrophia Myotonica 2,Myotonia Atrophica,Myotonia Dystrophica,Myotonic Dystrophy 1,Myotonic Dystrophy 2,PROMM (Proximal Myotonic Myopathy),Proximal Myotonic Myopathy,Ricker Syndrome,Steinert Myotonic Dystrophy,Steinert's Disease,Atrophica, Myotonia,Atrophicas, Myotonia,Congenital Myotonic Dystrophies,Disease, Steinert,Disease, Steinert's,Dystrophia Myotonica 2s,Dystrophia Myotonicas,Dystrophica, Myotonia,Dystrophicas, Myotonia,Dystrophies, Congenital Myotonic,Dystrophies, Myotonic,Dystrophy, Congenital Myotonic,Dystrophy, Myotonic,Dystrophy, Steinert Myotonic,Myopathies, Proximal Myotonic,Myopathy, Proximal Myotonic,Myotonia Atrophicas,Myotonia Dystrophicas,Myotonic Dystrophies,Myotonic Dystrophies, Congenital,Myotonic Dystrophy, Steinert,Myotonic Myopathies, Proximal,Myotonica, Dystrophia,Myotonicas, Dystrophia,PROMMs (Proximal Myotonic Myopathy),Proximal Myotonic Myopathies,Steinerts Disease,Syndrome, Ricker
D009841 Oligonucleotides Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed) Oligonucleotide
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense

Related Publications

Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Cellular delivery of locked nucleic acids (LNAs).
August 2002, Current protocols in nucleic acid chemistry,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Preparation of C5-functionalized locked nucleic acids (LNAs).
March 2011, Current protocols in nucleic acid chemistry,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Applications of peptide nucleic acids (PNAs) and locked nucleic acids (LNAs) in biosensor development.
April 2012, Analytical and bioanalytical chemistry,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA.
June 2007, Biochemistry,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.
January 2006, Progress in molecular and subcellular biology,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.
May 2000, Proceedings of the National Academy of Sciences of the United States of America,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Design of antisense oligonucleotides stabilized by locked nucleic acids.
May 2002, Nucleic acids research,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Pyrene-functionalized oligonucleotides and locked nucleic acids (LNAs): tools for fundamental research, diagnostics, and nanotechnology.
December 2011, Chemical Society reviews,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Locked nucleic acids (LNAs) reveal sequence requirements and kinetics of Xist RNA localization to the X chromosome.
December 2010, Proceedings of the National Academy of Sciences of the United States of America,
Agnieszka Wojtkowiak-Szlachcic, and Katarzyna Taylor, and Ewa Stepniak-Konieczna, and Lukasz J Sznajder, and Agnieszka Mykowska, and Joanna Sroka, and Charles A Thornton, and Krzysztof Sobczak
Initial observations of 99mTc labelled locked nucleic acids for antisense targeting.
November 2004, Nuclear medicine communications,
Copied contents to your clipboard!